ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > biogen suffering ?

<< Previous

Bullboard Posts

Next >>

Comment by M101on Sep 29, 2022 5:37pm

110 Views

Post# 34996074

RE:RE:RE:RE:RE:biogen suffering ?

I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than similarities. It's almost October, the baseball analogies practically write themselves. Lecanemab is a longer pop fly than Aducanumab, but they're both outs. Credit the player with making contact as opposed to all the earlier whiffs, but outs are still how you lose.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it